A rare cancer that forms in the ampulla of Vater, ampullary adenocarcinoma is a relatively unknown disease. It represents approximately 0.2% of all gastrointestinal cancers and 6% of periampullary tumors.1
At the NCCN 2022 Annual Conference, Stephen W. Behrman, MD, Professor of Surgery, The University of Tennessee Health Science Center, highlighted the presentation and clinical evaluation of ampullary adenocarcinoma, discussed current management and outcomes, and introduced the inaugural 2022 NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) for this disease.
Park W, Chawla A, O’Reilly EM, et al. Pancreatic cancer: a review [published correction appears in JAMA 2021;326:2081]. JAMA 2021;326:851–862.
Stiles ZE, Behrman SW, Deneve JL, et al. Ampullary adenocarcinoma: defining predictors of survival and the impact of adjuvant therapy following surgical resection for stage I disease. J Surg Oncol 2018;117:1500–1508.
Moekotte AL, van Roessel S, Malleo G, et al. Development and external validation of a prediction model for survival in patients with resected ampullary adenocarcinoma. Eur J Surg Oncol 2020;46:1717–1726.
Ecker BL, Vollmer CM Jr, Behrman SW, et al. Role of adjuvant multimodality therapy after curative-intent resection of ampullary carcinoma. JAMA Surg 2019;154:706–714.
Nassour I, Hynan LS, Christie A, et al. Association of adjuvant therapy with improved survival in ampullary cancer: a national cohort study. J Gastrointest Surg 2018;22:695–702.
Ramaswamy A, Bhandare M, Bal M, et al. Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas: are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine? HPB (Oxford) 2020;22:376–382.
- Search Google Scholar
- Export Citation
, Ramaswamy A , Bhandare M , Bal M Clinico-pathological correlates and survival outcomes in 214 resected ampullary adenocarcinomas: are outcomes different in intestinal and pancreatobiliary subtypes with adjuvant gemcitabine?HPB (Oxford) 2020; 22: 376– 382. 10.1016/j.hpb.2019.07.006 31405778
Al Abbas AI, Falvello V, Zenati M, et al. Impact of adjuvant chemotherapy regimen on survival outcomes in immunohistochemical subtypes of ampullary carcinoma [published online December 15, 2019]. J Surg Oncol, doi: 10.1002/jso.25808
Vo NP, Nguyen HS, Loh EW, et al. Efficacy and safety of adjuvant therapy after curative surgery for ampullary carcinoma: a systematic review and meta-analysis. Surgery 2021;170:1205–1214.
Yamashita S, Overman MJ, Wang H, et al. Pathologic response to preoperative therapy as a novel prognosticator for ampullary and duodenal adenocarcinoma. Ann Surg Oncol 2017;24:3954–3963.
Guo M, Beal EW, Miller ED, et al. Neoadjuvant therapy versus surgery first for ampullary carcinoma: a propensity score-matched analysis of the NCDB. J Surg Oncol 2021;123:1558–1567.
Wong W, Lowery MA, Berger MF, et al. Ampullary cancer: evaluation of somatic and germline genetic alterations and association with clinical outcomes. Cancer 2019;125:1441–1448.